166 related articles for article (PubMed ID: 12452037)
21. Microvessel density, proliferating activity, p53 and bcl-2 expression in in situ ductal carcinoma of the breast.
Zolota V; Gerokosta A; Melachrinou M; Kominea A; Aletra C; Scopa CD
Anticancer Res; 1999; 19(4B):3269-74. PubMed ID: 10652623
[TBL] [Abstract][Full Text] [Related]
22. P53 expression in patients with malignant and benign breast diseases.
Kalogeraki A; Panayiotides J; Tamiolakis D; Tzardi M; Chaniotis V; Chalkiadakis G; Melissas J; Stiftsis D; Kanavaros P; Delides GS
Anticancer Res; 2000; 20(3A):1801-5. PubMed ID: 10928110
[TBL] [Abstract][Full Text] [Related]
23. Telomerase hTR and hTRT gene expression in oral precancerous lesions and squamous cell carcinomas.
Zhang L; Zhang W
Chin J Dent Res; 1999 May; 2(2):43-8. PubMed ID: 10863406
[TBL] [Abstract][Full Text] [Related]
24. Breast carcinogenesis. Transition from hyperplasia to invasive lesions.
Meteoglu I; Dikicioglu E; Erkus M; Culhaci N; Kacar F; Ozkara E; Uyar M
Saudi Med J; 2005 Dec; 26(12):1889-96. PubMed ID: 16380768
[TBL] [Abstract][Full Text] [Related]
25. Biological indicators of aggressiveness in T1 ductal invasive breast cancer.
Bucci B; Carico E; Rinaldi A; Froio F; Puce YM; D'Agnano I; Vecchione A; Brunetti E
Anticancer Res; 2001; 21(4B):2949-55. PubMed ID: 11712792
[TBL] [Abstract][Full Text] [Related]
26. Alteration of cyclin D1 in Chinese patients with breast carcinoma and its correlation with Ki-67, pRb, and p53.
Guo LL; Gao P; Wu YG; Jian WC; Hao CY; Li H; Lin XY
Arch Med Res; 2007 Nov; 38(8):846-52. PubMed ID: 17923265
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
[TBL] [Abstract][Full Text] [Related]
28. Cyclin D1 gene amplification and protein expression in benign breast disease and breast carcinoma.
Zhu XL; Hartwick W; Rohan T; Kandel R
Mod Pathol; 1998 Nov; 11(11):1082-8. PubMed ID: 9831206
[TBL] [Abstract][Full Text] [Related]
29. Cytogenetic and molecular genetic changes in malignant transformation of immortalized esophageal epithelial cells.
Shen ZY; Xu LY; Chen MH; Cai WJ; Shen J; Chen JY; Zeng Y
Int J Mol Med; 2003 Aug; 12(2):219-24. PubMed ID: 12851721
[TBL] [Abstract][Full Text] [Related]
30. Combined evaluation of expression of telomerase, survivin, and anti-apoptotic Bcl-2 family members in relation to loss of differentiation and apoptosis in human head and neck cancers.
Sharma H; Sen S; Mathur M; Bahadur S; Singh N
Head Neck; 2004 Aug; 26(8):733-40. PubMed ID: 15287041
[TBL] [Abstract][Full Text] [Related]
31. Bax expression in untreated breast cancer: an immunocytometric study of 255 cases.
Martínez-Arribas F; Martín-Garabato E; Zapardiel I; Sánchez J; Lucas AR; Tejerina A; Schneider J
Anticancer Res; 2008; 28(5A):2595-8. PubMed ID: 19035283
[TBL] [Abstract][Full Text] [Related]
32. Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis.
Andrews GA; Xi S; Pomerantz RG; Lin CJ; Gooding WE; Wentzel AL; Wu L; Sidransky D; Grandis JR
Head Neck; 2004 Oct; 26(10):870-7. PubMed ID: 15390206
[TBL] [Abstract][Full Text] [Related]
33. [Expression of telomerase and p53 in ameloblastoma].
Zhong M; Zhang LH; Wang J; Zhang B; Hou L
Shanghai Kou Qiang Yi Xue; 2003 Apr; 12(2):127-31. PubMed ID: 14661519
[TBL] [Abstract][Full Text] [Related]
34. Telomerase activity and Bcl-2 expression in human breast cancer.
Elkak AE; Kirkpatrick K; Mears L; Wells C; Ghilchik M; Newbold R; Mokbel K
Eur J Surg Oncol; 2002 Feb; 28(1):14-8. PubMed ID: 11869007
[TBL] [Abstract][Full Text] [Related]
35. Immunofluorometric study of Bcl-2 and Bax expression in clinical fresh tumor samples from breast cancer patients.
Martínez-Arribas F; Núñez-Villar MJ; Lucas AR; Sánchez J; Tejerina A; Schneider J
Anticancer Res; 2003; 23(1B):565-8. PubMed ID: 12680147
[TBL] [Abstract][Full Text] [Related]
36. Haploid loss of bax leads to accelerated mammary tumor development in C3(1)/SV40-TAg transgenic mice: reduction in protective apoptotic response at the preneoplastic stage.
Shibata MA; Liu ML; Knudson MC; Shibata E; Yoshidome K; Bandey T; Korsmeyer SJ; Green JE
EMBO J; 1999 May; 18(10):2692-701. PubMed ID: 10329616
[TBL] [Abstract][Full Text] [Related]
37. Bcl-2 expression correlates with lymphovascular invasion and long-term prognosis in breast cancer.
Neri A; Marrelli D; Roviello F; DeMarco G; Mariani F; DeStefano A; Megha T; Caruso S; Corso G; Cioppa T; Pinto E
Breast Cancer Res Treat; 2006 Sep; 99(1):77-83. PubMed ID: 16541314
[TBL] [Abstract][Full Text] [Related]
38. Expression of cyclooxygenase-2 in breast carcinogenesis and its relation to HER-2/neu and p53 protein expression in invasive ductal carcinoma.
Cho MH; Yoon JH; Jaegal YJ; Choi YD; Lee JS; Lee JH; Nam JH; Choi C; Lee MC; Park CS; Woo Juhng S; Min KW
Breast; 2006 Jun; 15(3):390-8. PubMed ID: 16169726
[TBL] [Abstract][Full Text] [Related]
39. Regulation of telomerase and its hTERT messenger in colorectal cancer.
Boldrini L; Faviana P; Gisfredi S; Donati V; Zucconi Y; Ursino S; Simi P; Baldinotti F; Berti P; Galleri D; Materazzi G; Basolo F; Miccoli P; Pingitore R; Fontanini G
Oncol Rep; 2004 Feb; 11(2):395-400. PubMed ID: 14719074
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical study of apoptosis-related Bcl-2 protein and its correlation with proliferation indices (Ki67, PCNA), tumor suppressor genes (p53, pRb), the oncogene c-erbB-2, sex steroid hormone receptors and other clinicopathological features, in normal, hyperplastic and neoplastic endometrium.
Mitselou A; Ioachim E; Kitsou E; Vougiouklakis T; Zagorianakou N; Makrydimas G; Stefanaki S; Agnantis NJ
In Vivo; 2003; 17(5):469-77. PubMed ID: 14598611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
